TABLE 1.
Upregulation of lipid-related genes in DC-17
| Probeset ID | Gene Symbol | Gene Name | GO Pathways | Mean Expression ± SD in DCs | Mean Expression ± SD in DC-17s | Fold Change |
| 211748_x_at | PTGDS | Prostaglandin D2 synthase | (1, 2) | 219 ± 41 | 31,871 ± 9,162 | 146 |
| 212884_x_at | APOE | Apolipoprotein E | (1–3, 5, 6) | 725 ± 618 | 35,527 ± 7,100 | 49 |
| 207092_at | LEP | Leptin | (1–3) | 5 ± 2 | 196 ± 184 | 40 |
| 213553_x_at | APOC1 | Apolipoprotein C-I | (1–3, 5, 6) | 1,107 ± 1,334 | 43,123 ± 11,867 | 39 |
| 203979_at | CYP27A1 | Cytochrome P450, family 27, subfamily A, polypeptide 1 | (1) | 273 ± 232 | 10,520 ± 1,104 | 39 |
| 208792_s_at | CLU | Clusterin | (1, 5, 6) | 151 ± 35 | 4,454 ± 2,000 | 30 |
| 218922_s_at | LASS4 | LAG1 homolog, ceramide synthase 4 | (1, 2, 4, 7) | 6 ± 1 | 166 ± 71 | 28 |
| 202575_at | CRABP2 | Cellular retinoic acid binding protein 2 | (1, 2) | 647 ± 934 | 13,916 ± 10,024 | 22 |
| 203920_at | NR1H3 | Nuclear receptor subfamily 1, group H, member 3 | (1–3) | 414 ± 316 | 8,599 ± 3,457 | 21 |
| 228716_at | THRB | Thyroid hormone receptor, β | (3) | 49 ± 30 | 607 ± 359 | 13 |
| 211026_s_at | MGLL | Monoglyceride lipase | (1) | 666 ± 436 | 7,799 ± 1,620 | 12 |
| 223432_at | OSBP2 | Oxysterol binding protein 2 | (1, 5, 6) | 17 ± 7 | 175 ± 104 | 11 |
| 204561_x_at | APOC2 | Apolipoprotein C-II | (1–3, 5, 6) | 783 ± 650 | 8,095 ± 4,286 | 10 |
| 203423_at | RBP1 | Retinol binding protein 1, cellular | (1, 2) | 154 ± 90 | 1,433 ± 460 | 9 |
| 202481_at | DHRS3 | Dehydrogenase/reductase (SDR family) member 3 | (1, 2) | 203 ± 146 | 1,865 ± 621 | 9 |
| 223952_x_at | DHRS9 | Dehydrogenase/reductase (SDR family) member 9 | (1, 2) | 509 ± 521 | 4,517 ± 2,390 | 9 |
| 209785_s_at | PLA2G4C | Phospholipase A2, group IVC | (1, 2) | 324 ± 338 | 2,730 ± 879 | 8 |
| 209122_at | PLIN2 | Perilipin 2 | (5, 6) | 1,808 ± 681 | 14,885 ± 5,347 | 8 |
| 225847_at | KIAA1363 | Arylacetamide deacetylase-like 1 | (1) | 950 ± 922 | 7,426 ± 1,463 | 8 |
| 210942_s_at | SIAT10 | ST3 β-galactoside α-2,3-sialyltransferase 6 | (1, 2, 4) | 275 ± 178 | 2,061 ± 412 | 8 |
| 1555416_a_at | ALOX15B | Arachidonate 15-lipoxygenase, type B | (1, 2) | 63 ± 15 | 439 ± 262 | 7 |
| 218099_at | HT008 | Testis expressed 2 | (1, 2, 4, 7) | 742 ± 153 | 5,003 ± 1,727 | 7 |
| 205934_at | PLCL1 | Phospholipase C-like 1 | (1) | 270 ± 135 | 1,788 ± 841 | 7 |
| 228713_s_at | DHRS10 | Hydroxysteroid (17-β) dehydrogenase 14 | (1) | 201 ± 71 | 1,238 ± 448 | 6 |
| 238524_at | CEPT1 | Choline/ethanolamine phosphotransferase 1 | (1, 2) | 137 ± 103 | 840 ± 172 | 6 |
| 235678_at | GM2A | GM2 ganglioside activator | (1, 2, 4–7) | 3,285 ± 2,814 | 18,962 ± 5,607 | 6 |
| 227379_at | OACT1 | Membrane-bound O-acyltransferase domain containing 1 | (1, 2) | 285 ± 144 | 1,601 ± 899 | 6 |
| 201050_at | PLD3 | Phospholipase D family, member 3 | (1) | 3,941 ± 3,361 | 21,463 ± 2,991 | 5 |
| 200785_s_at | LRP1 | Low-density lipoprotein-related protein 1 | (1) | 463 ± 368 | 2,436 ± 806 | 5 |
| 220675_s_at | C22orf20 | Patatin-like phospholipase domain containing 3 | (1, 2) | 45 ± 13 | 182 ± 37 | 4 |
| 207275_s_at | ACSL1 | Acyl-CoA synthetase long-chain family member 1 | (1–3) | 1,368 ± 590 | 5,473 ± 486 | 4 |
| 1552637_at | PTPN11 | Protein tyrosine phosphatase, nonreceptor type 11 | (1, 2) | 12 ± 4 | 47 ± 9 | 4 |
| 208771_s_at | LTA4H | Leukotriene A4 hydrolase | (1, 2) | 4,728 ± 716 | 17,889 ± 3,425 | 4 |
| 203505_at | ABCA1 | ATP-binding cassette, subfamily A (ABC1), member 1 | (1, 5, 6) | 1,965 ± 476 | 7,339 ± 783 | 4 |
| 221675_s_at | CHPT1 | Choline phosphotransferase 1 | (1, 2) | 1,600 ± 343 | 5,964 ± 604 | 4 |
List of the top 50% of human genes from microarray analyses, showing the greatest mRNA expression fold change in DC-17s compared with untreated DCs among all genes found in the seven lipid-related GO pathways. The GO pathways are as follows: (1) lipid metabolic process, (2) cellular lipid metabolic process, (3) regulation of lipid metabolic process, (4) membrane lipid metabolic process, (5) lipid localization, (6) lipid transport, and (7) sphingolipid metabolic process. When several probe sets were available for a given gene, the probe set with the most significant overexpression in DC-17s versus DCs was selected. The fold change DC-17/DC was calculated from the mean expression in DC-17s (n = 5) and DCs (n = 4).